Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more
Oneness Biotech Co Ltd (4743) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.001x
Based on the latest financial reports, Oneness Biotech Co Ltd (4743) has a cash flow conversion efficiency ratio of 0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$14.32 Million) by net assets (NT$10.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oneness Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Oneness Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oneness Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oneness Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JiangSu JiangHuai Engine Co Ltd
SHE:000816
|
0.007x |
|
SK ETERNIX CO LT
KO:475150
|
0.497x |
|
Tianshui Zhongxing Bio-technology Co Ltd
SHE:002772
|
0.042x |
|
Vallourec SA
PINK:VLOWY
|
0.033x |
|
Hyosung TNC Corp
KO:298020
|
0.097x |
|
Shenzhen Sunwin Intelligent
SHE:300044
|
-0.017x |
|
Cohort plc
F:C7K
|
0.067x |
|
Luye Pharma Group Ltd
PINK:LYPHF
|
0.108x |
Annual Cash Flow Conversion Efficiency for Oneness Biotech Co Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Oneness Biotech Co Ltd from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$12.80 Billion | NT$-345.58 Million | -0.027x | +0.94% |
| 2023-12-31 | NT$14.50 Billion | NT$-395.13 Million | -0.027x | +53.97% |
| 2022-12-31 | NT$14.88 Billion | NT$-881.00 Million | -0.059x | -188.75% |
| 2021-12-31 | NT$14.09 Billion | NT$-288.89 Million | -0.021x | -278.41% |
| 2020-12-31 | NT$13.76 Billion | NT$158.14 Million | 0.011x | +134.81% |
| 2019-12-31 | NT$6.46 Billion | NT$-213.25 Million | -0.033x | -1295.85% |
| 2018-12-31 | NT$2.17 Billion | NT$-5.12 Million | -0.002x | +96.43% |
| 2017-12-31 | NT$2.49 Billion | NT$-165.27 Million | -0.066x | -54.05% |
| 2016-12-31 | NT$2.52 Billion | NT$-108.54 Million | -0.043x | +16.46% |
| 2015-12-31 | NT$2.77 Billion | NT$-142.34 Million | -0.051x | +34.05% |
| 2014-12-31 | NT$1.93 Billion | NT$-150.98 Million | -0.078x | -71.90% |
| 2013-12-31 | NT$1.97 Billion | NT$-89.26 Million | -0.045x | -364.04% |
| 2012-12-31 | NT$1.40 Billion | NT$24.15 Million | 0.017x | +180.32% |
| 2011-12-31 | NT$1.37 Billion | NT$-29.27 Million | -0.021x | -115.21% |
| 2010-12-31 | NT$1.09 Billion | NT$153.25 Million | 0.141x | +252.19% |
| 2009-12-31 | NT$1.11 Billion | NT$-102.30 Million | -0.092x | -- |